CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders

Parkinsonism and Related Disorders

Volumn 20, Issue 4, 2014, Pages 382-387

  Mondello, Stefania ^a   Constantinescu, Radu ^b   Zetterberg, Henrik ^b,c   Andreasson, Ulf ^b   Holmberg, Björn ^a   Jeromin, Andreas ^d  

^a UNIVERSITY OF MESSINA   (Italy)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Atlantic Biomarkers LLC   (United States)

Author keywords

Atypical parkinsonian disorders; Cerebrospinal fluid; Parkinson's disease; UCH L1; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; UBIQUITIN; UBIQUITIN CARBOXY TERMINAL HYDROLASE L1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; UBIQUITIN THIOLESTERASE; UCHL1 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; TAUOPATHY;

AGED; ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PARKINSONIAN DISORDERS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAUOPATHIES; UBIQUITIN THIOLESTERASE;

EID: 84897962640     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.01.011     Document Type: Article

References (33)

1. Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125:861-870.
2. Schneeberger A., Mandler M., Mattner F., Schmidt W. Vaccination for Parkinson's disease. Parkinsonism Relat Disord 2012, 18(Suppl.1):S11-S13.
3. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001, 2:589-594.
4. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., et al. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395:451-452.
5. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999, 53:1858-1860.
6. Hutter C.M., Samii A., Factor S.A., Nutt J.G., Higgins D.S., Bird T.D., et al. Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease. Eur J Neurol 2008, 15:134-139.
7. Osaka H., Wang Y.L., Takada K., Takizawa S., Setsuie R., Li H., et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 2003, 12:1945-1958.
8. Healy D.G., Abou-Sleiman P.M., Quinn N., Ahmadi K.R., Ozawa T., Kamm C., et al. UCHL-1 gene in multiple system atrophy: a haplotype tagging approach. Mov Disord 2005, 20:1338-1343.
9. Barrachina M., Castano E., Dalfo E., Maes T., Buesa C., Ferrer I. Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. Neurobiol Dis 2006, 22:265-273.
10. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatry 1992, 55:181-184.
11. Gilman S., Low P.A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C.J., et al. Consensus statement on the diagnosis of multiple system atrophy. JAutonomic Nervous Syst 1998, 74:189-192.
12. Litvan I., Agid Y., Calne D., Campbell G., Dubois B., Duvoisin R.C., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996, 47:1-9.
13. Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013, 80:496-503.
14. Mondello S., Linnet A., Buki A., Robicsek S., Gabrielli A., Tepas J., et al. Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery 2012, 70:666-675.
15. Mondello S., Buki A., Italiano D., Jeromin A. alpha-Synuclein in CSF of patients with severe traumatic brain injury. Neurology 2013, 80:1662-1668.
16. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
17. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T.F., Pepivani I., et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008, 213:315-325.
18. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C., Schlossmacher M.G. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011, 10:230-240.
19. Hall S., Ohrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012, 69:1445-1452.
20. Mondello S., Papa L., Buki A., Bullock M.R., Czeiter E., Tortella F.C., et al. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care 2011, 15:R156.
21. Ehrenreich H., Kastner A., Weissenborn K., Streeter J., Sperling S., Wang K.K., et al. Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol Med 2011, 17:1306-1310.
22. Engelender S. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. Autophagy 2008, 4:372-374.
23. Mackenzie I.R. Neuropathology of atypical parkinsonian disorders. Atypical parkinsonian disorders 2005, Humana Press. I. Litvan (Ed.).
24. Maraganore D.M., Lesnick T.G., Elbaz A., Chartier-Harlin M.C., Gasser T., Kruger R., et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 2004, 55:512-521.
25. Liu Z., Meray R.K., Grammatopoulos T.N., Fredenburg R.A., Cookson M.R., Liu Y., et al. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A 2009, 106:4635-4640.
26. Tomlinson Identifying targets in alpha-synuclein metabolism to treat Parkinson's and related disorders. Protein misfolding diseases: current and emerging principles and therapies 2010, 817-841. John Wiley and Son, Hoboken, NJ. M.K.J. Ramirez-Alvarado, C.M. Dobson (Eds.).
27. Holmberg M., Duyckaerts C., Durr A., Cancel G., Gourfinkel-An I., Damier P., et al. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet 1998, 7:913-918.
28. Constantinescu R., Rosengren L., Johnels B., Zetterberg H., Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord 2010, 16:142-145.
29. Parnetti L., Chiasserini D., Bellomo G., Giannandrea D., De Carlo C., Qureshi M.M., et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011, 26:1428-1435.
30. Boeve B.F., Lang A.E., Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003, 54(Suppl.5):S15-S19.
31. Lee S.E., Rabinovici G.D., Mayo M.C., Wilson S.M., Seeley W.W., DeArmond S.J., et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011, 70:327-340.
32. Ling H., O'Sullivan S.S., Holton J.L., Revesz T., Massey L.A., Williams D.R., et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain: J Neurol 2010, 133:2045-2057.
33. Scaravilli T., Tolosa E., Ferrer I. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. Mov Disord: Off J Mov Disord Soc 2005, 20(Suppl.12):S21-S28.